🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Harold J. Burstein

Harvard University

ORCID: 0000-0003-1963-8162

Also affiliated with Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Dana-Farber Brigham Cancer Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.742Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

medRxiv(2023)10.1101/2023.03.06.23286772
Top 27%
0.742DataRank
Top 27%12 citations

Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong +24 more

Papers

Driven by 7 papers — median percentile 73. Top paper: “Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT”.

Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

Journal of Clinical Oncology(2022)10.1200/jco.22.01065
N/A
2.2DataRank · unranked
59 citations

Gini F. Fleming, István Láng, Eva Ciruelos, Hervé Bonnefoi, Meritxell Bellet +22 more

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

Annals of Oncology(2023)10.1016/j.annonc.2023.08.004
N/A
1.7DataRank · unranked
58 citations

Timothy Blewett, Xun Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong +24 more

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

medRxiv(2023)10.1101/2023.03.06.23286772
Top 27%
0.742DataRank
Top 27%12 citations

Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong +24 more

Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa113
N/A
0DataRank · unranked
48 citations

Laura H. Hendrix, Terry Hyslop, William T. Barry, Eric P. Winer, Clifford A. Hudis +27 more

Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial)

UNC Libraries(2020)10.17615/e33z-ag80
N/A
0DataRank · unranked
0 citations

Harold J. Burstein, Lisa A. Carey, Antonio C. Wolff, Sara M. Tolaney, P. Kelly Marcom +15 more

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

UNC Libraries(2020)10.17615/3qn5-sn85
N/A
0DataRank · unranked
0 citations

Lisa A. Carey, Beth Overmoyer, Constance Cirrincione, William M. Sikov, Mehra Golshan +9 more

Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

UNC Libraries(2020)10.17615/7w8k-g207
N/A
0DataRank · unranked
0 citations

Ann Crawford, Annick D. Van den Abbeele, Rebecca Gelman, Steven E. Come, Xiaochun Li +13 more